MedTech News
.................... by Andrew Celentano
B. Braun Announces Approval and Commercialization of First Generic Sugammadex Injection in the U.S. Market
B. Braun Medical Inc. announced the FDA approval of Sugammadex Injection, 200 mg/2 mL (100 mg/mL), AP-rated generic BRIDION®1* (Sugammadex Injection) in the U.S. market.
Newronika picks up CE mark for adaptive deep brain stim
Newronika announced today that it secured CE mark for its latest adaptive deep brain stimulation (aDBS) system.
Contact-free sensors could help track movement symptoms in Parkinson’s disease
Disease progression in people with Parkinson’s disease can be accurately monitored using sensors, removing some of the limitations of wearable technologies, a new study reports.
Researchers develop a safer, more reliable material for growing small-scale models of the human gut
Scientists can use patient-derived tissue samples to grow miniature versions of human organs, allowing them to test new medications and disease treatments for personalized care.
Embolx Secures New CMS HCPCS Level II G-Code for Pressure-Generating Catheter Procedures Performed in the Physician Office (OBL)
SUNNYVALE, Calif., July 13, 2026 /PRNewswire/ — Embolx, Inc., a leader in advanced microcatheter technology for targeted embolization procedures, today announced that the Centers for Medicare & Medicaid Services (CMS) has established a new HCPCS Level II code, G0577, covering Sniper® procedures performed in the physician office, or office-based lab (OBL), setting. The new code took effect July 1, 2026.
FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer’s disease
STOCKHOLM, July 13, 2026 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the US Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for a once weekly lecanemab irmb subcutaneous injection (US brand name: Leqembi Iqlik®) as a starting dose for the treatment of early Alzheimer’s disease. The US launch is planned for late August 2026.
HistoSonics wins CE mark for Edison histotripsy system
HistoSonics announced today that it received CE mark approval for its Edison non-invasive histotripsy technology platform.
Claria Medical earns FDA nod for tissue containment, removal device for hysterectomy
Claria Medical announced today that it received FDA de novo authorization for its Claria system for minimally invasive hysterectomies.